MSCAN: ctDNA Methylation as Prognostic and Theranostic Tool for Pancreatic Cancer
NCT07045571 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000
Last updated 2025-07-01
Summary
Developing a characteristic ctDNA methylation panel for pancreatic ductal adenocarcinoma and establishing an intelligent diagnostic and dynamic monitoring model based on ctDNA methylation.
Conditions
- Pancreatic Neoplasm
- Pancreas Cancer
Sponsors & Collaborators
-
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
collaborator OTHER -
Ruijin Hospital
collaborator OTHER -
Changhai Hospital
collaborator OTHER -
Yingbin Liu, MD, PhD, FACS
lead OTHER
Principal Investigators
-
Yinbin Liu, PhD · RenJi Hospital
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-10-30
- Primary Completion
- 2026-01-22
- Completion
- 2026-07-22
Countries
- China
Study Locations
More Related Trials
-
Phase ǀ Study on Pancreatic Cancer Treated by CyberKnife
NCT02716207 ·Status: COMPLETED ·Phase: NA
-
Early Diagnosis of Pancreatic Cancer Via Deciphering Multi-modal Immunological Signatures
NCT06495749 ·Status: NOT_YET_RECRUITING
-
Tumor Exosome Liquid Biopsy Strategy to Diagnose Pancreatic Cancer
NCT06108531 ·Status: ENROLLING_BY_INVITATION
-
Early Detection of Pancreatic Cancer
NCT05596435 ·Status: UNKNOWN
-
sCD8, as a Novel Biomarker for Pancreatic Cancer
NCT05500027 ·Status: RECRUITING
-
The Role of ctDNA, PVT1 and ROS in Diagnosis and Treatment of Gastrointestinal and Hepatobiliary Pancreatic Cancer
NCT03076502 ·Status: UNKNOWN
-
Identification of Biomarkers for Early Detection of Pancreatic Cancer
NCT00897494 ·Status: COMPLETED
-
Integrative Proteomic Characterization of Pancreatic Ductal Adenocarcinoma
NCT04525209 ·Status: UNKNOWN
-
Early-stage Detection of LIver, Biliary TRAct and PancReatic Cancers
NCT06139042 ·Status: RECRUITING
-
CtDNA-guided Maintenance Therapy in Pancreatic Cancer
NCT07054879 ·Status: RECRUITING
-
Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer
NCT02278458 ·Status: UNKNOWN ·Phase: PHASE1
-
Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites
NCT05745233 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
The Significance and Indications of Surgery for Synchronous Liver Metastatic Pancreatic Cancer
NCT06873178 ·Status: ACTIVE_NOT_RECRUITING
-
Circulating Cell-free Tumor DNA(ctDNA) in Pancreatic Cancer
NCT02934984 ·Status: UNKNOWN
-
AssesSment of Early-deteCtion basEd oN liquiD Biopsy in PANCEATIC Cancer (ASCEND-PANCREATIC)
NCT05556603 ·Status: RECRUITING
-
Gene Expression Profiles in Patients With Metastatic Pancreatic Cancer
NCT00897741 ·Status: COMPLETED
-
Prognostic Biomarkers of Pancreatic Cancer Based on Proteomic Techniques
NCT05289895 ·Status: UNKNOWN
-
Prognostic Biomarkers of Pancreatic Cancer Based on Proteomics Techniques
NCT05088161 ·Status: UNKNOWN
-
Circulating Extracellular Exosomal Small RNA as Potential Biomarker for Human Pancreatic Cancer
NCT04636788 ·Status: UNKNOWN ·Phase: NA
-
A Cohort Study on ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer
NCT07080021 ·Status: RECRUITING
-
Development of a New Immunochemistry Method Using Antibodies of Proteins Related Pancreatic Cancer
NCT04293497 ·Status: COMPLETED ·Phase: NA
-
Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma
NCT05483257 ·Status: COMPLETED
-
A Combination of AKR1B10 and CA19-9 Improves the Diagnosis of PDAC
NCT04726956 ·Status: COMPLETED
-
Decitabine Combined With Gemcitabine in First-line Treatment of AdvancedPancreatic Cancer
NCT02685228 ·Status: UNKNOWN ·Phase: NA
-
Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer
NCT07117045 ·Status: RECRUITING